Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842001 | 0.83 | ARG1 (0.33) | ARG1ARG2 | |
| SCHEMBL11947206 | 0.81 | HRH4 (0.35) | ARG1ARG2 | |
| SCHEMBL13884361 | 0.79 | HRH4 (0.37) | ARG1ARG2 | |
| SCHEMBL20812158 | 0.79 | HRH4 (0.37) | ARG1ARG2 | |
| SCHEMBL20812165 | 0.79 | HRH4 (0.37) | ARG1ARG2 | |
| SCHEMBL13884349 | 0.79 | HRH4 (0.37) | ARG1ARG2 | |
| SCHEMBL10226405 | 0.79 | HRH4 (0.37) | ARG1ARG2 | |
| SCHEMBL14509576 | 0.79 | HRH4 (0.37) | ARG1ARG2 | |
| SCHEMBL22893234 | 0.79 | — | — | |
| SCHEMBL22996200 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230216082-A1 | POLYELECTROLYTE COMPOSITES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-07-06 | — | — | US | disclosed |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080009504-A1 | Antifungal agents | SCYNEXIS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| WO-2004099200-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | ARG1 554/4885ARG2 1664/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | ARG1 2764/4885ARG2 3948/4885 |
| US-20090048300-A1 | Heterocyclic Compounds | HDAC1, HDAC3, HDAC11 | ARG1 3099/4885ARG2 1187/4885 |
| US-20080009504-A1 | Antifungal agents | DPM1, MAN2B1, MAN2A1 | ARG1 180/4885ARG2 1096/4885 |
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | ARG1 147/4885ARG2 156/4885 |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | ASGR1, CUTA, SRPRA | ARG1 2420/4885ARG2 4610/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | ARG1 4059/4885ARG2 4025/4885 |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | ARG1 12/4885ARG2 101/4885 |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | ARG1 2420/4885ARG2 4610/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | ARG1 15/4885ARG2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.